‘Starving’ brain tumours to death
Exploring alterations in amino acid metabolism as novel therapeutic targets in paediatric glial tumours using advanced metabolomics methods
Killing dormant leukaemia cells to stop relapse
Targeting refractory and dormant stem cells in childhood leukaemia
Phase II clinical trial: Can a new drug help treat relapsed or refractory (not responding to treatment) ALK+ anaplastic large cell lymphoma?
NIVO-ALCL - Phase II trial of nivolumab for paediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (Cohort 2)
A new way of treating poor prognosis Wilms’ tumour
Targeting gain of function p53 in poor prognosis Wilms' tumour via histone methyltransferase inhibition
Improving our understanding of immunotherapy in high-risk neuroblastoma
Understanding and improving the mechanism of action of anti-GD2 monoclonal antibody therapy in neuroblastoma
Investigating novel drug combinations for acute myeloid leukaemia
Identifying Combination Therapies Targeting Apoptosis pathways in Paediatric AML (CAuSAL study)
Using repurposed drugs to repair the damage that causes acute myeloid leukaemia
Targeting mutant NRAS in paediatric AML
Using an antibody 'smart bomb' to help the body fight cancer
Targeting Myeloid-Derived Suppressor Cells (MDSCs) and Tumour-Associated Macrophages (TAMs) with the anti-CD33 immunotoxin Gemtuzumab ozogamicin to restore anti-cancer immunity
Repurposing existing drugs to improve outcomes in Ewing sarcoma
Repurposing of drugs targeting drug resistant self-renewing Ewing’s sarcoma cells to accelerate new treatments into clinical trials to improve outcomes.